HOME >> BIOLOGY >> NEWS
JCI Table of Contents, 1 October, 2003

rcinogenesis and for the design of new approaches to the prevention and treatment of breast cancer.

TITLE: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression

AUTHOR CONTACT:
Lalage Wakefield
National Cancer Institute, Bethesda, Maryland, USA.
Phone: 301-496-8351
Fax: 301-496-8395
Email: wakefiel@dce41.nci.nih.gov

View the PDF of this article at: https://www.the-jci.org/press/18899.pdf


Mutant gene accounts for some cases of congenital heart disease

Sick sinus syndrome (SSS) was first described in 1967 and is characterized by arrhythmia, palpitations, and fainting. Although frequently associated with heart disease and seen most often in the elderly, SSS may occur in the fetus, infant or child without apparent cause. In these cases, it is presumed to be congenital. D. Woodrow Benson and colleagues at Children's Hospital Medical Center in Cincinnati, Ohio, screened 10 pediatric SSS patients from 7 families for mutations in the alpha subunit of the cardiac sodium channel gene (SCN5A) a gene previously associated with cardiac rhythm disorders - and found that 5 individuals carrying mutations in this gene demonstrated a loss of sodium channel function, predicted to reduce excitability of the heart. This study reveals that congenital SSS, in some families, is a recessive disorder of the cardiac sodium channel.

TITLE: Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A)

AUTHOR CONTACT:
D. Woodrow Benson
Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Phone: 513-636-7716
Fax: 513-636-5958
Email: woody.benson@cchmc.org

View the PDF of this article at:

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... , ... February 21, 2017 , ... ... organizations to build connected digital health applications, announced a partnership with Redox, a ... to seamlessly connect to many clinical systems while keeping data secure in the ...
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of stem cells ... multiple areas of medicine, due to their differentiating characteristics. Stem cells are unique as ... ability to be induced to become tissue or organic-specific cells with special functions. ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017  OncoGenex ... apatorsen results from two randomized Phase 2 clinical trials were ... Genitourinary Cancers Symposium, held February 16 th - 18 th ... trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated ... treatments. ...
(Date:2/21/2017)...   Invitae Corporation (NYSE: NVTA), one of ... members of the company,s management team will present at ... on Monday, March 6, 2017 at approximately 4:00 p.m. ... Massachusetts . The live, listen-only ... the investors section of the company,s website at ...
Breaking Biology Technology:
Cached News: